Skip to main content

Table 4 Design characteristics of AdaPT in comparison to other trials

From: First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation

 

VALUE[16]

ASCOT-BPLA[17]

DREAM[6, 38]

AdaPT

 

Valsartan

Amlodipine

Amlodipine

Atenolol

Ramipril

Placebo

ACEi

Diuretic

 

(n = 7649)

(n = 7596)

(n = 9639)

(n = 9618)

(n = 2.623)

(n = 2.646)

(n = 1.353)

(n = 662)

Study design

RCT

RCT

RCT

Observational study

Endpoint

New onset diabetes (secondary objective)

New onset diabetes (tertiary objective)

New onset diabetes or death (primary endpoint)

New onset diabetes (primary evaluation criterion)

Inclusion criteria

        

   Age (years)

≥ 50

40–79

≥ 30

≥ 45

   Hypertension

160–210/<115 mmHg

≥ 160/100 mmHg

n.a.

≥ 140/90 mmHg

   Fasting plasma glucose

normal

Normal

110–125 mg/dl [6.1–7.0 mmol/l]

110–125 mg/dl [6.1–7.0 mmol/l]

   Impaired glucose tolerance

normal

Normal

140–199 mg/dl [7.8–11.0 mmol/l]

no inclusion criterion

Exclusion criteria

        

   Diabetes

exclusion (for diabetes endpoint)

exclusion (for diabetes endpoint)

exclusion

exclusion

   Cardiovascular disease

possible

Possible

exclusion

possible

Follow-up (years)

4.2 (mean)

5.5 (median)

3.0 (median)

4 (planned)

HR new-onset diabetes

0.77 [95%CI 0.69–0.86]

0.70 [95%CI 0.63–0.78]

0.91 [95%CI 0.80–1.03]

n.a.

  1. n.a. = not available